medigraphic.com
ISSN 0016-3813 (Print)

2002, Number S1

<< Back Next >>

Gac Med Mex 2002; 138 (S1)

Molecular Biology and Treatment of Chronic Myeloid Leukemia

I. Molecular Biology of Chronic Myeloid Leukemia.
II. Importance of Establishing Chronic Myeloid Leukemia Prognostic Factors in Treatment with Alpha Interferon.

Cervera CEE, Meillón-García L

Language: Spanish
References: 28
Page: 102-105
PDF size: 38.14 Kb.


Text Extraction

No abstract


REFERENCES

  1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.

  2. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341;164-72.

  3. Holyoake TL. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 2001;113:11-23.

  4. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84.

  5. Bedi A, Zehnbauer BA, Barber J, Sharkis S, Jones R. Inhibition of apoptosis by BCR-ABL in chronic myeolid leukemia. Blood 1994;83:2038-44.

  6. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-94.

  7. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. German CML Study Group. Blood 1994;84:4064-4077.

  8. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa 2a as compared with conventional chemotherapy for the treatment of chronic myelogenous leukemia. N Engl J Med 1994;330:820-825.

  9. Allan NC, Richards SM, Sheperd PC. UK Medical Research Council Randomized, Multicenter Trial of Interferon-Alpha for Chronic Myeloid Leukemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-1397.

  10. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86:906-916.

  11. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon on allogenic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-1536.

  12. The Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol 1999;17:1858-1868.

  13. Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philadelphia chromosone-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose citarabine. J Clin Oncol 1999;17:284-292.

  14. Meillon L, Oropeza P, Arana R, et al. Treatment of chronic myelogenous leukemia (CML) with interferon alpha and hydroxyurea. Rev Invest Clin 1994(Suppl);(Abstract 394).

  15. Baccarani M. Non-transplant treatment options for patients with newly diagnosed chronic myeloid leukemia. Education Program Book. American Society of Hematology. Orlando, Fl. 2001.98-103.

  16. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good risk” chronic granulocytic leukemia. Blood 1984; 63:789-799.

  17. Kantarjian HM, Keating MJ, Smith TL, et al. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990;88:1-8.

  18. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia trated with interferon alfa. J Natl Cancer Inst 1998; 90:850-858.

  19. Bonifazi F, de Vivo A, Rosti G, et al. for The European Study Group on Interferon on Chronic Myeloid Leukemia. Blood 2001; 98:3074-3081.

  20. Mahon FX, Faberes C, Pueyo S, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon. Blood 1998;92:405-409.

  21. Sinclair PB, Nacheva EP, Levasha M, et al. Large deletions at the t(9:22) breakpoint are common and my identify a poor prognosis sub-group of patients with chronic myeloid leukemia. Blood 2000;95:738-744.

  22. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells form patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000; 95:1883-1890.

  23. Barthe C, Mahon FX, Gharbi MJ, et al. Expression of interferon-a (IFNa) receptor 2c at diagnosis is associated with cytogenetic response in IFNa-treated chronic myeloid leukemia. Blood 2001; 97:3568-3573.

  24. Schmidt M, Hochhaus A, Nitsche A, et al. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to Interferon-a. Blood 2001; 97:3648-3650.

  25. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998;352:1087-1092.

  26. Tura S. Important questions related to interferon-alpha therapy in chronic myeloid leukemia. Education Program Book. San Francisco, CA, USA: American Society of Hematology. 2000. p. 95-97.

  27. Goldman JM, Drucker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-2042.

  28. Sheperd P, Kluinelemans H, Richards S, et al: A randomized comparison of low or high dose IFNa in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups. Blood 2001;98:727a.




2020     |     www.medigraphic.com